Company Active LTD

Company profile

Dxcover Limited

The Future of Cancer Diagnostics | Dxcover

Our mission is to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers. Early diagnosis beats cancer.

CRN

SC535447

Founded

2016

Age

Overview

Legal name

DXCOVER LIMITED

Region

Unknown

Registered address

5 ROBROYSTON OVAL

NOVA TECHNOLOGY PARK

GLASGOW

CITY OF GLASGOW

SCOTLAND

G33 1AP

Insolvency history

Corporate ownership

Updated 06 Jun 2026 16:52

Controls 1

Dxcover Limited

No active corporate controller recorded.

Latest accounts

Financial period: 1 Jan 2024 to 31 Dec 2024

FULLACCOUNTS

Turnover

Unknown

Profit / Loss

Unknown

Employees

Company events

Reference milestones and recent Companies House filing stream events.

6 events

29 May

2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep

2026

Accounts due

Accounts Due

Next accounts due date

15 May

2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec

2024

Accounts filed

Accounts

Last accounts made up date

30 Sep

2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQzNzY4MDA2N2FkaXF6a2N4

Published 30 Sep 2024 08:24

16 May

2016

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards

First funded

2019

Funded years

2019, 2020, 2023

Age at first award

3 years

Projects

2023 EU-Funded Lead participant

EMBRACE - Early detection of Brain Cancer using a novel spectroscopic liquid biopsy enabling timely detection and diagnosis for patient benefit

1 Jul 2023 to 30 Jun 2025

Awarded

£2,117,150

Total cost £3,500,000

no public description

2020 Feasibility Studies Lead participant

ClinSpec Dx: Serum Diagnostics For Cancer (Extension of Live Project due to COVID-19)

1 Jun 2020 to 30 Nov 2020

Awarded

£160,378

Total cost £160,378

no public description

2019 Collaborative R&D Lead participant

ClinSpec Dx: Serum Diagnostics for Cancer

1 Jun 2019 to 28 Feb 2021

Awarded

£258,594

Total cost £517,187

"ClinSpec Dx is developing the world's first cost-effective blood test for brain cancer and aims to develop other fast, sensitive blood tests for the early detection of other cancers and other diseases. Our next-generation liquid biopsy diagnostic approach analyses the entire biomolecular complement of human serum and when combined with our machine learni...

Product types

Collaborative R&D EU-Funded Feasibility Studies